Home › All Companies › AVTX › Annual Report

Avalo Therapeutics, Inc. (AVTX) — Annual Report

AI-Powered SEC Filing Analysis

← All AVTX filings
Latest Annual Report Filed: 2026-03-23

Key Insights

  • Avalo Therapeutics, Inc. reported a significant increase in revenue from its product Milliprex over the past two years, indicating potential growth for the company.
  • The company has been actively pursuing partnerships and acquisitions, including the Almata Bio transaction, which could provide opportunities for further product development and expansion.
  • Avalo Therapeutics has a substantial amount of non-current derivative liabilities and other liabilities, which could present financial risks if not properly managed.
Sentiment: Neutral Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-23. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Avalo Therapeutics, Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.